Related Experiment Video
Updated: Feb 26, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Recent Advances in Stroke Prevention in Patients with Atrial Fibrillation and End-Stage Renal Disease
Federico Ronco1, Patrizio Mazzone2, Leila Hosseinian3
1Interventional Cardiology, Cardiovascular Department, ULSS-12 Veneziana, Venice and Mestre, Italy.
Insights
For patients with end-stage renal disease and atrial fibrillation, vitamin K antagonists are less effective for stroke prevention and increase bleeding risk. Left atrial appendage occlusion shows promise as a safer alternative.
Area of Science:
- Nephrology
- Cardiology
- Thrombosis
Background:
- Chronic kidney disease (CKD) is common in patients with atrial fibrillation (AF), but optimal stroke prevention is unclear.
- Vitamin K antagonists (VKA) have an uncertain risk/benefit profile in this population.
- End-stage renal disease (ESRD) patients on hemodialysis experience reduced VKA efficacy and increased bleeding risk.
Purpose of the Study:
- To evaluate stroke prevention strategies in AF patients with CKD.
- To assess the safety and efficacy of novel oral anticoagulants (NOACs) in CKD patients.
- To explore Left Atrial Appendage (LAA) occlusion as an alternative therapy.
Main Methods:
- Review of existing literature on anticoagulation in CKD and AF.
- Analysis of post hoc data from clinical trials on NOACs in moderate renal impairment (eGFR 30-50 mL/min).
- Examination of preliminary data on LAA occlusion in CKD patients.
Main Results:
- VKA are less effective and riskier for stroke prevention in ESRD patients with AF.
- NOACs show promise in moderate renal impairment, but data for eGFR <30 mL/min is lacking.
- LAA occlusion demonstrates comparable efficacy and safety in CKD patients.
Conclusions:
- Stroke prevention in ESRD patients with AF remains a challenge with limited evidence.
- NOACs require further investigation for severe CKD (eGFR <30 mL/min).
- LAA occlusion may emerge as a standard of care for stroke prevention in ESRD patients with AF.
Background:
Chronic kidney disease (CKD) is associated with a high prevalence of atrial fibrillation (AF), but in this population the risk/benefit ratio of anticoagulant therapy with vitamin K antagonists (VKA) for thromboprophylaxis is uncertain.
Summary:
In end-stage renal disease (ESRD) patients undergoing hemodialysis, VKA seem less effective in stroke prevention than in the general population, with an increased risk of major bleeding. Recently, novel oral anticoagulant agents (NOACs) have proven to be effective for stroke prevention in AF and have demonstrated an improved safety profile compared to VKA. Limited data from post hoc analyses of controlled clinical trials suggest the safe and effective use of NOACs in patients with moderate renal impairment (i.e., estimated glomerular filtration rate, eGFR, between 30 and 50 mL/min). The question still remains whether NOACs can be used in patients with an eGFR <30 mL/min, since there are no studies addressing this subject. In fact, patients with CKD stage 4 and 5 were excluded from controlled clinical trials on anticoagulation therapy for stroke prevention in AF. Left atrial appendage (LAA) occlusion represents a nonpharmacological alternative for stroke prevention in patients with AF who are difficult to manage medically. Preliminary data indicate a similar efficacy and safety profile in patients with CKD compared to patients with normal renal function.
Key Messages:
Stroke prevention in patients with ESRD and AF represents a clinical challenge with poor evidence. LAA occlusion may become the standard of care for stroke prevention in patients with ESRD and AF.
Related Concept Videos
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:23Atherosclerosis IV: Nursing Management
01:30Heart Failure V: Medical Management
01:29Venous Thrombosis III: Interprofessional Care
01:22Acute Kidney Injury VI: Nursing Management